ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Pharmaceuticals

Samsung Biologics bumps Hyundai from Korean market's top 3

Drugmaker's market cap surges to $31bn on lucrative virus treatment deal

Samsung Biologics benefits from the clean room expertise of fellow group member Samsung Electronics. (Photo courtesy of Samsung Biologics)
KOTARO HOSOKAWA, Nikkei staff writer | South Korea

SEOUL -- Samsung Biologics has become South Korea's third-most-valuable company, besting the much larger Hyundai Motor thanks to its status as a rare winner in the coronavirus economy.

Read Next

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more

By continuing to browse this website, you accept cookies which are used for several reasons such as personalizing content/ads and analyzing how this website is used. Please review our Cookie Policy to learn how you can update your cookie settings.

Accept & Continue Close